What is Merck's new revenue projection by the mid-2030s?

Merck forecasts $70 billion in revenue from its new growth drivers by the mid-2030s.

Why is Merck accelerating drug launches ahead of Keytruda competition?

Merck is accelerating launches to bolster revenue from new drugs as competition for its blockbuster cancer therapy, Keytruda, approaches.

Home / Business and Economy / Merck Eyes $70B Revenue From New Drugs by Mid-2030s

Merck Eyes $70B Revenue From New Drugs by Mid-2030s

Q: How has Merck's outlook for cardiometabolic and respiratory treatments changed?

Merck now expects cardiometabolic and respiratory treatments to generate about $20 billion, an increase from the previous $15 billion forecast.

13 Jan

•

Summary

Merck anticipates $70 billion in revenue from new growth drivers by the mid-2030s.
Cardiometabolic and respiratory treatments revenue forecast increased to $20 billion.
Infectious disease drug revenue projection significantly raised to $15 billion.

Merck Eyes $70B Revenue From New Drugs by Mid-2030s

Merck is strategically accelerating its drug launch pipeline, forecasting substantial revenue growth from new business areas. By the mid-2030s, the company anticipates generating approximately $70 billion from these emerging drivers. This proactive approach is designed to counter the looming competitive pressures on its highly successful cancer treatment, Keytruda.

Specifically, Merck has revised its revenue projections upwards for key therapeutic categories. The outlook for cardiometabolic and respiratory treatments has been increased to an estimated $20 billion, up from a prior forecast of $15 billion. This adjustment highlights a strengthened belief in the market potential for these therapies.

Furthermore, the drugmaker has significantly enhanced its expectations for infectious disease drugs, now projecting them to contribute around $15 billion in revenue. This represents a considerable increase from the earlier estimate of $5 billion, indicating a robust pipeline and growing market confidence in Merck's advancements in combating infectious diseases.